NCT00706316View on ClinicalTrials.gov

Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

November 30, 2012

Conditions
Nasopharyngeal Cancer
Interventions
BIOLOGICAL

EBV-Specific CTLs and CD45 Mab

"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT00706316 - Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer | Biotech Hunter | Biotech Hunter